Looking Back on a Successful 2013 and a Glance Ahead at a Promising 2014

December 31, 2013
Tim Mayleben
President and Chief Executive Officer

Esperion had an incredible year in 2013 with more successes, both clinically and financially, than in any other year since we were founded in April 2008 as the new Esperion. We executed on all of our milestones – all toward our goal of bringing ETC-1002 to market. A unique, first-in-class, oral, once-daily investigational small molecule,… Read More

Posted In: Company News